Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies

A technology of FMU-EPCAM-2A9, 1. FMU-EPCAM-2A9, applied in the field of monoclonal antibodies, can solve the problems of antibody drug hypersensitivity and the like

Active Publication Date: 2010-05-05
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the mouse-derived antibody drug is used in the human body, due to its immunogenicity, it will cause an immune response in the human body, resulting in the clearance of the antibody drug or hypersensitivity mediated by immune complexes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies
  • Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies
  • Variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0031] The applicant immunized BALB / c mice with recombinant human EPCAM, prepared a group of mouse anti-human EPCAM monoclonal antibodies, and screened a hybridoma cell line that can stably secrete FMU-EPCAM-2A9 monoclonal antibody with high affinity against human EPCAM , Prepare ascites fluid to obtain high-affinity anti-human EPCAM monoclonal antibody. Confirm the uniqueness of the gene sequence and corresponding protein sequence and its CDR sequence; provide support for anti-human EPCAM chimeric or humanized genetic engineering antibodies.

[0032] The present invention will be described in detail below in conjunction with the accompanying drawings, which are explanations of the present invention rather than limitations.

[0033] The present invention is specifically implemented according to the following steps:

[0034] 1 Preparation of mouse anti-human EPCAM high-affinity antibody

[0035] 1.1 Preparation and purification of monoclonal antibodies

[0036] Design primer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses variable regions of light chains and heavy chains of FMU-EPCAM-2A9 monoclonal antibodies. The amino acid sequence of a monoclonal antibody light chain variable region is shown as SEQ ID NO.1, and the amino acid sequence of a monoclonal antibody heavy chain variable region is shown as SEQ ID NO.2. A set of mouse anti-human EPCAM monoclonal antibodies are prepared through recombining human EPCAM immune BALB/c mice, and hybridoma cell lines capable of stably secreting high-affinity anti-human EPCAM monoclonal antibodies are screened to prepare ascitic fluid so as to obtain the high-affinity anti-human EPCAM monoclonal antibodies. The uniqueness of the gene sequence and a corresponding protein sequence and a CDR sequence of the gene sequence are confirmed so as to provide supports for anti-human EPCAM chimeric or humanized gene engineering antibodies.

Description

technical field [0001] The invention belongs to the field of biomedical technology, and relates to a monoclonal antibody, in particular to a light chain and heavy chain variable region of an anti-human EPCAM FMU-EPCAM-2A9 monoclonal antibody, including its amino acid sequence and nucleotide sequence . Background technique [0002] Epithelial cell adhesion molecule (EPCAM) was originally discovered as a dominant epitope in colon cancer, and it was considered to be a reliable binding site for cell adhesion and therapeutic antibodies. Current studies believe that EPCAM is a glycosylated type I transmembrane glycoprotein with a molecular weight of 30 to 40kD. Its structure includes an epidermal growth factor-like and a thyroglobulin-like extracellular region, a transmembrane region and a Cytoplasmic domain of 26 amino acids. In normal cells, EPCAM is mainly located in the tight junction of the epithelial cell space. As shown by the intensity and frequency of EPCAM expression,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C12N15/13G01N33/577
Inventor 金伯泉杨琨张葵宋朝君孙元杰谢鑫朱参胜
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap